Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4017 participants.
Also called NCT04564742
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,017 participants
- Sponsor
- Registry
-
NCT04564742 -
2020-000664-31
-
- Other papers using this trial's data
- Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04564742. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-22 (actual); primary completion 2023-07-05 (actual). Results posted on 2025-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
- Acronym
- DAPA-MI
- Condition
- Acute Myocardial Infarction
- Condition
- Heart Failure
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Uppsala University
Record details
- Record id
cardio:ct-nct04564742- Content hash
41a5ba6a54f4375210d4e8455f673a486438906eed8bfe770e0f1ab83fa81bbc